Open Access
Table 1
Comparison between clinical and geographic data of the responder and non-responder groups involved in the study.
| Patient data | Responders (n = 23) | Non-responders (n = 21) |
|---|---|---|
| Gender | ||
| Female | 11 (47.8%) | 7 (33.3%) |
| Male | 12 (52.2%) | 14 (66.7%) |
| Age (mean) | ||
| Mean ± SD | 36.04 ± 11.13 | 32.29 ± 13.37 |
| Number of skin lesions | ||
| Median (min–max) | 1 (1–7) | 1 (1–15) |
| Lesion location | ||
| Lower extremity | 10 (43.5%) | 13 (61.9%) |
| Upper limbs | 7 (30.4%) | 6 (28.6%) |
| Head and cervical-facial | 1 (4.3%) | 5 (23.8%) |
| Torso | 7 (30.4%) | 2 (9.5%) |
| Lesion-evolution time (days) | ||
| Median (min–max) | 60 (30–150) | 60 (20–270) |
| Number of treatmentsa | ||
| Median (min–max) | 1 (1–1) | 2 (2–4) |
| MST | ||
| Reactor | 22 (100%) | 18 (94.7%) |
| Non-reactor | – | 1 (5.3%) |
| MST values (mm)b | ||
| Median (min–max) | 20 (7–60) | 12 (4–27) |
| ELISA | ||
| Reactor | 16 (76.2%) | 17 (89.5%) |
| Non-reactor | 5 (23.8%) | 2 (10.5%) |
| IIFc | ||
| Reactor | 9 (42.9%) | 17 (94.4%) |
| Non-reactor | 12 (57.1%) | 1 (5.6%) |
| Region of Infection | ||
| Rio de Janeiro | 18 (78.3%) | 17 (81%) |
| Other states | 5 (21.7%) | 4 (19%) |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.